IL327010A - Methods of treating cancer using ilt2 antibodies and combination therapies - Google Patents

Methods of treating cancer using ilt2 antibodies and combination therapies

Info

Publication number
IL327010A
IL327010A IL327010A IL32701026A IL327010A IL 327010 A IL327010 A IL 327010A IL 327010 A IL327010 A IL 327010A IL 32701026 A IL32701026 A IL 32701026A IL 327010 A IL327010 A IL 327010A
Authority
IL
Israel
Prior art keywords
ilt2
antibodies
methods
treating cancer
combination therapies
Prior art date
Application number
IL327010A
Other languages
Hebrew (he)
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of IL327010A publication Critical patent/IL327010A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL327010A 2023-09-12 2024-09-12 Methods of treating cancer using ilt2 antibodies and combination therapies IL327010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363582093P 2023-09-12 2023-09-12
PCT/US2024/046388 WO2025059304A2 (en) 2023-09-12 2024-09-12 Methods of treating cancer using ilt2 antibodies and combination therapies

Publications (1)

Publication Number Publication Date
IL327010A true IL327010A (en) 2026-05-01

Family

ID=95021872

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327010A IL327010A (en) 2023-09-12 2024-09-12 Methods of treating cancer using ilt2 antibodies and combination therapies

Country Status (2)

Country Link
IL (1) IL327010A (en)
WO (1) WO2025059304A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365637B2 (en) * 2010-02-19 2016-06-14 Japan Science And Technology Agency Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide
MA47468A (en) * 2017-02-09 2019-12-18 Bluefin Biomedicine Inc ANTI-ILT3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
JP2022553108A (en) * 2019-10-23 2022-12-21 リビジェン バイオファーマ ホールディングス リミテッド Anti-CD40 binding molecules and bispecific antibodies including such
AU2021265801B2 (en) * 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof
EP4277926A1 (en) * 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CA3231508A1 (en) * 2021-09-15 2023-03-23 Calvin J. Kuo Methods of amplifying tumor-reactive immune populations using organoids
IL315487A (en) * 2022-03-07 2024-11-01 Agenus Inc Anti-ilt2 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2025059304A2 (en) 2025-03-20
WO2025059304A3 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
IL313807A (en) Claudin18 antibodies and methods of treating cancer
IL276446A (en) Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
EP3906061A4 (en) Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
SG11202108525VA (en) Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
IL299339A (en) Antibodies and methods for treating claudin-associated diseases
IL304600A (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2022006147A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies.
EA201991870A1 (en) TREATMENT OF BLADDER CANCER USING AN ANTIBODY TO PD-L1
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
IL318694A (en) Anti-ccr8 antibodies and methods of use
CA3304061A1 (en) Methods of treating cancer using ilt2 antibodies and combination therapies
EP4251214A4 (en) Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents
IL319193A (en) Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer
IL316751A (en) Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
IL312813A (en) Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
IL307556A (en) Methods of treating cancer with anti-tigit antibodies
IL321145A (en) Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
ZA202204252B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
CA3275305A1 (en) Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
CA3273665A1 (en) Methods of treating cancer using anti-ddr1 antibodies and immune checkpoint inhibitors
HK40073192A (en) Claudin18 antibodies and methods of treating cancer
IL315250A (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
IL317551A (en) Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer
IL319991A (en) Treatment of cancers using combinations of smarca2 degraders and kras targeting therapies